Articles

The FDA warned healthcare professionals about potential medication errors resulting from confusion with the nonproprietary name for the recently approved breast cancer drug ado-trastuzumab emtansine (Kadcyla; also known as T-DM1).

Hollywood, FL—At the Third Annual Conference of the Association for Value-Based Cancer Care, James Lang, PharmD, Vice President of Pharmacy Services at BlueCross BlueShield of Michigan (BCBSM), shared his company’s approach to new managed market challenges.

Hollywood, FL—At the Third Annual Conference of the Association for Value-Based Cancer Care, Sandra M. Swain, MD, FACP, President of the American Society of Clinical Oncology (ASCO) and Medical Director of Washington Cancer Institute in Washington, DC, described efforts by ASCO to enhance the quality and cost-effectiveness of the cancer care its members provide.

Using data-sifting algorithms developed by computer scientists at Brown University, researchers are beginning to untangle the complex genetics of cancer. In a new study published in the New England Journal of Medicine, investigators have outlined the most complete genetic profile of acute myeloid leukemia (AML).

Endometrial cancer is the fourth most common malignancy among American women. The National Cancer Institute estimates that close to 50,000 women will be diagnosed with endometrial cancer in 2013; for a majority of women with aggressive, high-grade tumors, the 5-year survival rate is approximately 16%.